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AbstrACt
Introduction The therapeutic paradigm in Alzheimer’s 
disease (AD) has shifted towards secondary prevention, 
defined as an intervention aiming to prevent or delay 
disease onset in pre-symptomatic individuals at risk of 
developing dementia due to AD. The key feature of AD 
prevention is the need to treat years or even decades 
before the onset of cognitive, behavioural or functional 
decline. Prediction of AD risk and evaluation of long-term 
treatment outcomes in this setting requires predictive 
modelling and is associated with ethical concerns and 
social implications. The objective of this review is to 
identify and elucidate them, as presented in the literature.
Methods and analysis A systematic literature review 
was conducted in Medline, Embase, PsycInfo and Scopus, 
and was complemented with a grey literature search. 
All searches were conducted between March and July 
2018. Two reviewers independently assessed each study 
for inclusion and disagreements were adjudicated by a 
third reviewer. Data are now being extracted using an 
extraction sheet developed within the group of reviewers, 
based on an initial sample of three manuscripts, but 
allowing for inclusion of newly identified data items 
(ethical arguments). Data will be analysed qualitatively 
using a thematic analysis technique. Potential biases in 
selection and interpretation of extracted data are mitigated 
by the fact that reviewers come from a range of different 
scientific backgrounds and represent different types of 
stakeholders in this ethical discussion (academia, industry, 
patient advocacy groups).
Ethics and dissemination The study does not require 
ethical approval. The findings of the review will be 
disseminated in a peer-reviewed journal and presented 
at conferences. They will also be reported through the 
Innovative Medicine Initiative project: Real World Outcomes 
Across the AD Spectrum for Better Care: Multi-modal Data 
Access Platform (IMI: ROADMAP).
trial registration number CRD42018092205.
IntroduCtIon
Alzheimer’s disease (AD) is the cause of 70% 
of all dementias1 and a significant public 
health challenge both in the developed and 
the developing countries. Dementia due to 
AD is clinically characterised by cognitive 
and executive dysfunction, psychiatric symp-
toms and behavioural disturbances. It leads 
to difficulties performing activities of daily 
living and eventually to death.2 3 
Until recently, AD could be assumed from 
a relatively early age of patients at onset and 
clinical observation, yet the final diagnosis 
could only be made postmortem based on 
a brain autopsy.4 Treatment strategies for 
patients with assumed AD became available 
only at the end of the 20th century, through 
marketing authorisation for cholinesterase 
inhibitors indicated for mild to severe AD 
dementia. Shortly thereafter, N-methyl-D-as-
partate antagonist memantine was authorised 
for use in moderate to severe AD dementia. 
These treatments help manage dementia 
symptoms but do not alter substantially 
the disease course.5 The 21st century has 
seen a tremendous progress in the field of 
AD biomarkers discovery. Measuring these 
biomarkers, such as the presence of amyloid 
βeta (Aβ) plaques in brain or in the cerebro-
spinal fluid, is nowadays a routine practice in 
strengths and limitations of this study
 ► This is the first systematic literature review of the 
ethical concerns and social implications which arise 
due to recent scientific and technological progress 
which enables AD prevention at asymptomatic 
stages.
 ► Detailed and robust methodology was developed 
to ensure producing a possibly valid and complete 
ethical and social landscape of AD secondary pre-
vention using predictive modelling.
 ► Potential limitation of the study is that the current 
literature might not be sufficiently mature to capture 
all relevant ethical concerns and social implications.
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AD research and is slowly entering the clinical setting as 
well.6 Thanks to biomarker discovery, it became possible 
to more precisely distinguish between dementia due 
to AD versus other types. More importantly though, it 
became possible to identify potential AD patients in a 
preclinical stage which is characterised by elevated levels 
of AD biomarkers yet in the absence of clinical symp-
toms.7–9 This opens a new and potentially the only avenue 
for disease modifying AD treatment, particularly since of 
all phase three trials targeting symptomatic AD failed.10 It 
is now believed that the same drugs which were not effica-
cious in AD dementia might turn out disease modifying if 
used early enough.11
Recognition of a continuous character of AD, prog-
ress made towards identification of AD-like pathology in 
cognitively intact people and increasing belief that only 
early treatment can be disease modifying caused a major 
shift in the therapeutic paradigm in AD. This shift has 
been from dementia symptoms management to secondary 
prevention, understood as intervention in presymptom-
atic ‘at-risk’ individuals to prevent or delay disease onset.
Together with the technological progress made in the 
recent decades with regard to availability of patient’s data, 
diminishing cost of data storage and computing power, 
these developments make it now feasible to assess the risk 
of developing AD in large number of potential patients 
and implement preventive approaches in clinical practice 
or a public health measure.
Yet preventive approach in preclinical AD brings about 
numerous ethical concerns and social implications 
which, even if not specific to AD, require a close investi-
gation in this particular setting. What makes the case of 
AD distinct is apparent need to intervene years (or even 
decades) before the onset of cognitive, behavioural or 
functional declines which impact patients' lives,12 without 
having a sufficient understanding of causal mechanisms 
of the disease to assess long-term consequences of this 
intervention. In this setting where link between cause, 
intervention and the effect is uncertain and spread over 
a long period of time, the use of predictive modelling is 
particularly needed. Specific challenges of AD prevention 
and how predictive modelling can help address them, is 
summarised in table 1.
Predictive modelling can however act as double-edged 
sword and while facilitating some challenges arising in 
the context of AD prevention, it also adds numerous 
ethical concerns and social considerations potentially 
stemming from—among others—the risk of false classifi-
cation, the dependence of the results on the assumptions, 
and from the statistical complexity which makes it diffi-
cult to communicate the modelling concept and results 
to general public, and to an individual patient.
Table 1 Principles of secondary preventive approach as applied to Alzheimer's disease (AD) and the role of predictive 
modelling in this setting
Criteria
Prerequisites for a 
preventive approach AD-specific context Role of predictive modelling
Importance and 
public consensus
Large unmet public health 
causing a public concern.
Yes: there is a public consensus around the unmet 
need and its criticality.
Further to that, prevention might be the only feasible 
intervention in AD (speculative).
–
Costs Prevention is more 
cost effective than 
treatment over the lifetime 
of the patient.
Likely the case, given the AD burden, but not 
conclusive (until a specific intervention is evaluated).
Health-economic modelling with a 
long-term horizon depending on long-
term scenario.
Mechanism The natural course of 
disease is well understood.
The role of a myloid βeta (targeted by the currently 
developed drugs) for disease progression is only 
partially understood, therefore reducing its levels 
might not translate to improvement in clinical 
outcomes.
–
Selection of the 
population to receive 
intervention
Intervention is offered to all 
demographic segments in 
the population or specific 
screening procedure 
exists.
Population-wide treatment might not be appropriate 
(side effects, budget impact). Targeting a segment 
might be necessary but difficult to establish which 
one (only a partial match between the asymptomatic 
stage and AD, genetic markers not conclusive).
Identification of ‘at-risk’ patients from 
a general population or a predefined 
population with individual factors (eg, 
with genetic predisposition, family 
history, subjective memory complaint, 
etc.)
Efficacy of the 
treatment
A disease-modifying 
treatment exists.
Future phase three trials will conclude on some but 
not all meaningful outcomes.
Prediction of clinical outcomes and 
long-term based on biomarker status 
and its trajectory
(eg, cognition vs function and 
dependency).
Access to treatment Efficacious treatment is 
accessible and affordable.
Not possible to conclude until a specific intervention 
is known.
Identification of patient subgroups 
most likely to benefit from the 
treatment.
Source, criteria and prerequisites adapted from Khoury et al36 and Wilson and Jungner13
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The objective of this study is to systematically review 
and discuss the ethical concerns and social implications 
raised by the use of predictive modelling tools in the 
setting of secondary prevention of AD. Secondary preven-
tion is defined here as targeting presymptomatic patients 
who do not have mild cognitive impairment (MCI) but 
have a higher risk of developing MCI and then dementia 
due to AD than the general population with an interven-
tion aiming to prevent or delay the onset of a disease.13 14 
Predictive modelling is defined here as the use of data 
from multiple individual subjects, and statistical models 
to identify the likelihood of future outcomes based on 
historical data.15 Ethical concern is understood pragmati-
cally as a situation (actual or hypothetical) which requires 
a normative evaluation in the categories of right versus 
wrong.16 Social implications are defined as consequences 
of actual or hypothetical choices, enacted on a societal 
level, which provoke a moral deliberation on the ground 
of ethical principles.
Our specific research questions were identified via a 
preliminary, targeted literature search17 and include the 
following.
1. What are the ethical concerns and social implications 
associated with a) selection of a population for as-
sessment of the risk of developing AD via predictive 
modelling? b) the disclosure of individual risk of de-
veloping AD assessed using predictive modelling in 
asymptomatic patients? c) conditioning of access to fu-
ture AD treatment, based on the predictive modelling? 
d) assessment of the benefit-risk from AD treatment 
administered at preclinical stage, made using predic-
tive modelling?
2. What are the broader, population-level ethical con-
cerns and social implications of using predictive mod-
elling tools in the setting of secondary AD prevention?
3. What other ethical concerns and social implications 
are raised in this context?
The current social context of these considerations 
is a growing pressure from patients, carers, payers and 
providers to develop and introduce to the market a 
disease-modifying treatment and therefore alleviate 
the current and forecasted burden due to AD. For this 
reason, in this review the ethical concerns which stem 
both from the secondary prevention approach in AD and 
of forsaking this therapeutic paradigm will be considered.
MEthods And AnAlysIs
Protocol and registration
This protocol was prepared according to the reporting 
guidelines of the preferred reporting items for system-
atic reviews and meta-analysis for protocols 2015 (PRIS-
MA-P).18 19 The completed PRISMA-P checklist can be 
found in the online supplementary file 1. The review 
protocol was registered with the PROSPERO international 
prospective register of systematic reviews (registration 
number CRD42018092205) on April 6, 2018. The systematic 
review manuscript will be prepared following the PRISMA 
statement. Important amendments to this protocol will be 
reported and published with the results of the review.
study selection criteria
The search strategy was organised following the SPICE 
framework (setting, perspective, intervention, compar-
ison, evaluation).20
Setting: presymptomatic AD
Studies will be included if discussing asymptomatic/
pre-symptomatic individuals at-risk of AD, including those 
with subjective memory complaint/cognitive impair-
ment but without MCI diagnosis. Examples of phrases 
that would qualify a study for inclusion are: symptomatic 
patients with genetic predisposition, family history or 
the presence of AD biomarkers, AD treatment prior to 
onset, cognitively intact/normal AD, prodromal AD (but 
only when understood as asymptomatic) and abnormal 
biomarkers. Studies discussing only symptomatic stages of 
AD or discussing dementia secondary to other diseases, 
or other primary dementias will be excluded.
Perspective: individual and societal
Studies reporting on both the individual and societal 
perspective will be included.
Intervention: secondary AD prevention using predictive modelling
Studies will be included if discussing either the predictive 
modelling method (statistical algorithms) or source data 
(genetic data, imaging data, cerebrospinal fluid exam-
ination, family data, electronic/medical health record, 
family history, neurocognitive assessment, demographics, 
etc.) as a component of secondary AD prevention, aiming 
to prevent or delay the onset of MCI/AD dementia in 
presymptomatic individuals at risk of AD. Excluded will 
be studies discussing secondary prevention but without 
any component of predictive modelling (neither method 
nor data source) or which do not discuss secondary 
prevention of AD (eg, discuss tertiary prevention which is 
defined as targeting individuals with MCI and later in the 
disease course).
Evaluation: ethical and social implications
Studies will be included if they contain discussion or 
commentary on ethical concerns or social implications; 
otherwise will be excluded.
Study type
Studies will be included if reporting on the results of 
research on humans (basic, clinical, social, reviews/
meta-analyses, observational, Randomized Controlled 
Trials), including conference abstracts. Editorials, 
commentaries, guidelines, discussion and position papers, 
books and book chapters will also be included, regard-
less of whether they were peer-reviewed or not. Animal 
or in-vitro studies, study protocols, and book reviews will 
be excluded.
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Language
Only papers in English, French or German will be 
included.
Year of publication
Manuscripts/documents will be included if published 
from 2007 onwards. The choice of this time span reflects 
the fact that secondary prevention is a recent therapeutic 
strategy against AD, and therefore only relatively recent 
literature is expected to be relevant.
search strategy
Electronic databases
The literature was retrieved from the following data 
sources: Embase/Medline, Scopus and PsycINFO chosen 
collectively by the group of contributors, which included 
an information specialist. These databases were searched 
in two rounds, first time on 28 March 2018 and second 
time from 28 May to 31 May 2018 (coverage from the 
beginning of time until the search date). The reason for 
the two rounds of search was identification of additional 
keywords representing the same clinical phenomenon as 
well as improvement of syntax strategies which allowed 
identification of additional manuscripts. The exact 
search terms used in all databases are described in the 
online supplementary file 2. The database searches have 
now been completed. Automatic deduplication was used 
whenever possible.
Manual search (including grey literature)
Further relevant literature, including grey literature, 
defined as non-peer reviewed, publicly available docu-
ments was identified in a structured manner.21 22 First, a 
generic Google search engine was used and the first 10 
pages of results were reviewed for potentially relevant 
entries. Second, a targeted search within predefined 
websites was conducted, using Google interface. The list 
of websites, compiled by one of the reviewers and then 
consulted within the group of contributors, included: 
Alzheimer Europe (https://www. alzheimer- europe. 
org/); Alzheimer’s Association (https://www. alz. org/); 
Alzheimer’s Foundation of America (https:// alzfdn. 
org/); Alzheimer’s Society, UK (https://www. alzheimers. 
org. uk/); France Alzheimer (https://www. francealz-
heimer. org/); The World Health Organization (http://
www. who. int/) and The Organization for Economic 
Co-operation and Development (http://www. oecd. org/).
study selection
Study selection has been completed on October 8, 2018. 
References were managed in Excel and Mendeley. The 
removal of duplicates in terms of title and first author 
name as well as exclusion of manuscripts/documents due 
to the language and publication data was performed by 
one reviewer. The remaining manuscripts/documents 
were independently assessed (based on an abstract or 
executive summary) by two reviewers to determine eligi-
bility. Disagreements between the two reviewers were 
adjudicated by a third reviewer. Manuscripts/documents 
were classified and described according to the reason 
for exclusion. Reviewers had a possibility to exclude not 
eligible studies based on review of the full-text versions 
(prior to extraction).
data extraction
Full texts of manuscripts/documents potentially eligible 
for inclusion were then retrieved for data extraction. A 
single, qualitative review is now ongoing using a semi-
structured extraction sheet developed in a form of an 
online questionnaire where content (text) extracted by 
all reviewers uploads in real time into an online spread-
sheet for further qualitative data analysis.
The semistructured extraction sheet was developed in 
the following way: First, the following high-level sections 
of this sheet were predefined based on the research ques-
tions of this study and the methodologic requirements:
 ► Eligibility for extraction.
 ► Prespecified research questions
 – Selection of a population for risk assessment via 
predictive modelling.
 – Disclosure of individual risk assessed using predic-
tive modelling.
 – Treatment and conditioning of treatment access, 
based on predictive modelling.
 – Assessment of the benefit from treatment based on 
predictive modelling.
 – Broader social implications/concerns at a 
population level.
 – Other ethical/social issues.
 ► Reviewer’s conclusions and topics/themes to be 
further explored.
 ► Assessment of quality and relevance of a given study.
Second, each of the high-level section was populated 
with a specific list of ethical concerns or social implica-
tions. This list was derived by one reviewer from four 
studies,23–26 selected for this purpose by this reviewer and 
an independent bioethicist (who is a ROADMAP collabo-
rator but does not participate in this systematic literature 
review) out of a pool of around ~20 studies assessed as 
eligible at that point of time, based on an individual assess-
ment as to which studies are particularly comprehensive 
and/or informative. Third, open-ended text boxes were 
added to each high-level section to allow capturing all 
novel themes, arguments and considerations that were 
not initially included in the structured list. The extraction 
sheet was critically reviewed within the group of collabo-
rators and then refined.
data analysis
Qualitative data analysis of the data extracted to date is now 
ongoing. The aim of this review is to provide a compre-
hensive landscape of the ethical concerns and social 
implications related to the use of predictive modelling for 
secondary prevention of AD. Extracted data will be anal-
ysed qualitatively using a thematic analysis27 28 defined as 
'a method for identifying, analysing and reporting patterns 
(themes) within data which minimally organises and 
 o
n
 6 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026468 on 3 March 2019. Downloaded from 
5Angehrn Z, et al. BMJ Open 2019;9:e026468. doi:10.1136/bmjopen-2018-026468
Open access
describes (your) data set in (rich) detail but also interprets 
various aspects of the research topic’.21 Theme is defined 
as 'a repeated pattern of meaning, capturing something 
important about the data in relation to the research ques-
tion, and representing some level of patterned response 
or meaning within the data set’.27 In characterising salient 
ethical arguments the focus is on the claims being made 
and the arguments supporting them, not on quantitative 
assessment of the number of times a given claim appears in 
the literature. Therefore, the frequency will not be treated 
as a measure of importance.
The research questions of this study define the highest 
level themes. Ethical considerations, as present in the 
literature, will be inductively aggregated into subthemes 
which will lead to scrutinising, augmenting and refining 
the predefined highest level themes. In order to make 
sure that complex ethical arguments are understood in 
context, full-text papers will be revisited during the iter-
ative analytic process. Multiple rounds of analysis will be 
conducted based on extracted data grouped in matrices 
of hierarchical themes and then discussed, until there is a 
consensus within the group of collaborators that the anal-
ysis is accurate and possibly exhaustive, given the body of 
evidence. Tools supporting group interpretations will be 
used, such as web-based analysis spreadsheets which can 
be accessed and modified by all collaborators in real time.
risk of bias (quality) assessment
This is a systematic literature review conducted according 
to a pre-specified research protocol. Due to the qualitative 
character of the study objective and research questions, it 
aims to qualitatively understand a possibly wide spectrum 
of the problem and disregards the frequency with which 
a given ethical concern or social implication appears in 
the literature, which mitigates much of a possible bias 
in assessment of cumulative evidence. The validity and 
generalizability of this study lies in a rigorous method-
ology and the extent to which it is able to produce rich, 
informative description and inform further research.29
A potential bias might stem from some ethical arguments 
being missed or misinterpreted, when different reviewers 
appraise manuscripts and documents in a different manner. 
To mitigate this bias, and facilitate group interpretation, the 
team of reviewers participated in a face-to-face workshop 
on April 28, 2018 in Barcelona, during which the research 
objective, strategy and extraction tools were thoroughly 
discussed and reviewed when needed. Further to that, the 
reviewers involved in this study come from different back-
grounds and types of institutions, thereby minimising the 
overall bias of selective interpretation due to a pre-existing 
knowledge and perspective. More specifically, reviewers 1 
and 2 in this study are sociologists, reviewer 3 is a clinical 
psychiatrist, reviewer 4 is psychologist, reviewer 5 is a market 
access professional specialising in AD, reviewer is a pharma-
cist and market access professional, reviewer 7 is a mathe-
matician and statistical modeller. Other contributors to the 
study are information specialist and a market access profes-
sional specialising in AD. All reviewers are contributors 
to the Innovative Medicine Initiative project: Real World 
Outcomes Across the ADS pectrum for Better Care: Multi-
modal Data Access Platform (IMI: ROADMAP) project, in 
a WP8 dedicated to the ethical, legal and social implication 
of creating a Real World Data platform for AD research 
and come from a diverse background (industry, academia, 
patient advocacy group).
Patient and public involvement
Patients and public were not involved in the design of this 
study.
Ethics and dissemination
The study does not require ethical approval. The find-
ings of the review will be disseminated in a peer-reviewed 
journal and presented at conferences. They will also be 
reported through the IMI initiative Real World Outcomes 
across the AD spectrum for better care: multi-modal data 
access platform (ROADMAP).
discussion
This systematic literature review will provide a compre-
hensive picture of ethical concerns and social implica-
tions which arise in the setting of AD prevention, where 
patients without clinical symptoms but with elevated risk 
of developing AD in the future receive treatment years 
before the disease onset. We will consider both individual 
and societal perspective for a possibly complete review.
Focus on the ethical and social consequences of using 
predictive modelling tools in AD preventive setting is a 
logical and necessary step in this field, which noted signif-
icant advances in the recent years with serious implica-
tions for the clinical practice. For example, recently an 
algorithm was developed which classifies cognitively 
normal patients aged at least 70 years according to their 
risk of developing MCI with ~70% accuracy based on 
routinely collected health data only.30 The authors suggest 
that it could serve as a first-tier screening tool to prese-
lect patients for a more expensive or invasive screening 
which would, presumably, involve genetic testing and 
brain imaging. Others argue that regardless of the fact 
that preclinical AD diagnosis was developed as a primarily 
scientific concept to be used in AD research, it already 
entered the clinical setting due to a common practice 
of disclosing biomarker status and the associated risk6 
and commercial initiatives offering predictive tests to a 
general public. To date, many of the ethical and social 
concerns related to AD prevention were already identi-
fied and discussed, focusing on delivery of clinical care to 
AD patients,31 research ethics32 and some specific aspects 
of it, such as development of readiness cohorts for AD 
research,33 and using patient’s genetic information for 
research.34 Another topic which was widely discussed is 
the disclosure of genetic and biomarker risk factors to 
asymptomatic individuals participating in AD research.35 
However, to our knowledge, no study has explored and 
discussed the ethical and social implications of using 
predictive modelling in preventive AD setting. Given 
 o
n
 6 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026468 on 3 March 2019. Downloaded from 
6 Angehrn Z, et al. BMJ Open 2019;9:e026468. doi:10.1136/bmjopen-2018-026468
Open access 
the predictive nature of the current science in the AD 
domain, the technological developments in the recent 
years allowing to assess and potentially disclose individu-
al-level risk assessment on a mass scale, and the outlook 
of future therapeutics targeting now early stages of AD 
continuum, including asymptomatic patients at risk, an 
assessment of the ethical landscape is urgently needed.
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